This study is investigating a new treatment for adults who have previously had depression but are still experiencing cognitive impact (e.g. issues with memory). This research is being carried out at the University of Oxford.
The study will involve 7 visits over 1 month, including 2 MRI scans. Participants will be paid £20 per hour for taking part in the study (an estimated total of £700) plus reasonable travel expenses.
Adults aged 25-55 who have previously had depression
Syndesi Therapeutics. Conducted by Oxford University
January 31, 2022
The study will include taking the study drug each morning for 16 to 18 days and completing a number of questionnaires, memory and problem solving tasks. The study will include 7 visits to the study site (Warneford Hospital in Oxford), and two of these will include a magnetic resonance imaging (MRI) brain scan whilst completing some of the tasks.
This study is a ‘randomised’ study, which means that participants are put into one of 3 groups and each group is given a different treatment. Two doses of study drug, (1.0 mg SDI-118 or 5.0 mg SDI-118) or placebo (dummy drug) will be evaluated in 3 equal sized groups. Each participant will be put into one of the 3 groups by chance (randomly). You are more likely to receive study drug (approximately 67% chance) than placebo.
There are no direct benefits to you taking part in this study. However, the information we get from you will help us to understand more about the safety and tolerability of the study drug and how the study drug affects the performance of learning and memory tasks.
Participants will be paid £20 per hour for taking part in the study (an estimated total of £700) plus reasonable travel expenses.